Pyxis Oncology, Inc. (NASDAQ:PYXS) Given Average Recommendation of “Moderate Buy” by Analysts

Shares of Pyxis Oncology, Inc. (NASDAQ:PYXS) have received an average recommendation of “Moderate Buy” from the six analysts that are covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a hold recommendation and five have assigned a buy recommendation to the company. The average 12-month price objective among brokers that have updated their coverage on the stock in the last year is $9.20.

PYXS has been the topic of several research reports. Royal Bank of Canada reaffirmed an “outperform” rating and set a $8.00 price target on shares of Pyxis Oncology in a research note on Wednesday, March 19th. HC Wainwright reissued a “buy” rating and set a $5.00 price target on shares of Pyxis Oncology in a research report on Wednesday, March 19th.

Hedge Funds Weigh In On Pyxis Oncology

Institutional investors and hedge funds have recently modified their holdings of the stock. Intech Investment Management LLC bought a new position in shares of Pyxis Oncology during the third quarter worth approximately $55,000. MetLife Investment Management LLC increased its position in Pyxis Oncology by 41.1% during the 3rd quarter. MetLife Investment Management LLC now owns 18,818 shares of the company’s stock worth $69,000 after buying an additional 5,484 shares during the period. Jacobs Levy Equity Management Inc. bought a new position in Pyxis Oncology during the 3rd quarter worth $1,405,000. State Street Corp lifted its holdings in shares of Pyxis Oncology by 28.0% during the third quarter. State Street Corp now owns 951,251 shares of the company’s stock worth $3,491,000 after buying an additional 208,344 shares in the last quarter. Finally, Jane Street Group LLC grew its stake in shares of Pyxis Oncology by 40.8% in the third quarter. Jane Street Group LLC now owns 49,558 shares of the company’s stock valued at $182,000 after acquiring an additional 14,349 shares in the last quarter. 39.09% of the stock is currently owned by institutional investors and hedge funds.

Pyxis Oncology Stock Performance

PYXS opened at $1.09 on Friday. The company has a fifty day moving average price of $1.30 and a two-hundred day moving average price of $2.30. The firm has a market capitalization of $67.13 million, a PE ratio of -1.06 and a beta of 1.11. Pyxis Oncology has a 52 week low of $0.99 and a 52 week high of $6.18.

Pyxis Oncology (NASDAQ:PYXS) last announced its quarterly earnings results on Tuesday, March 18th. The company reported ($0.32) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.33) by $0.01. The firm had revenue of $16.15 million during the quarter. Equities analysts forecast that Pyxis Oncology will post -1.04 EPS for the current year.

About Pyxis Oncology

Pyxis Oncology, Inc, a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.